Sulfadoxine/Pyrimethamine intermittent preventive treatment for malaria during pregnancy

Emerging Infectious Diseases

Volumn 16, Issue 11, 2010, Pages 1666-1670

  Deloron, Philippe ^a,b   Bertin, Gwladys ^a,b   Briand, Valérie ^a,b   Massougbodji, Achille ^c   Cot, Michel ^a,b  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF ABOMEY CALAVI   (Benin)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR;

ARTICLE; BLOOD SMEAR; CLINICAL TRIAL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTYPE; HUMAN; INCIDENCE; LIVER TOXICITY; LOW BIRTH WEIGHT; MALARIA; MALARIA FALCIPARUM; PHENOTYPE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREGNANCY; PREVALENCE; SKIN MANIFESTATION;

ANTIMALARIALS; DRUG COMBINATIONS; FEMALE; HUMANS; MALARIA; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PYRIMETHAMINE; SULFADOXINE;

EID: 77958527083     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1611.101064     Document Type: Article

References (40)

1. Cot M, Deloron P. Malaria prevention strategies. Br Med Bull.2003; 67:137-48.DOI: 10.1093/bmb/ldg003
2. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. LancetInfect Dis. 2007; 7:93-104.DOI: 10.1016/S1473-3099(07)70021-X
3. World Health Organization. WHO Expert Committee on Malaria.Twentieth report. World Health Organ Tech Rep Ser. 2000;892:1-74.
4. Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, et al. Intermittent sulphadoxine-pyrimethamine to preventsevere anaemia secondary to malaria in pregnancy: a randomisedplacebo-controlled trial. Lancet. 1999; 353:632-6.DOI: 10.1016/S0140-6736(98)07318-8
5. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamineresistance on the effi cacy of intermittent preventivetherapy for malaria control during pregnancy: a systematic review. JAMA. 2007; 297:2603-16.DOI: 10.1001/jama.297.23.2603
6. East African Network for Monitoring Antimalarial Treatment (EANMAT).The efficacy of antimalarial monotherapies, sulphadoxinepyrimethamineand amodiaquine in East Africa: implications forsub-regional policy. Trop Med Int Health. 2003; 8:860-7.DOI:10.1046/j.1360-2276. 2003.01114.x
7. World Health Organization. Susceptibility of Plasmodium falciparumto antimalarial drugs: report on global monitoring: 1996-2004. Geneva: The Organization; 2005. WHO/HTM/MAL/2005.1103.
8. Aubouy A, Jafari S, Huart V, Migot-Nabias F, Mayombo J, Durand R, et al. Dhfr and dhps genotypes of Plasmodium falciparum isolatesfrom Gabon correlate with in vitro activity of pyrimethamine and cycloguanil,but not with sulfadoxine-pyrimethamine treatment effi cacy.J Antimicrob Chemother. 2003; 52:43-9.DOI: 10.1093/jac/dkg294
9. Faucher JF, Aubouy A, Adeothy A, Doritchamou J, Cottrell G, Gourmel B, et al. Comparison of sulfadoxine-pyrimethamine, un supervisedartemether-lumefantrine, and unsupervised artesunateamodiaquinefi xed-dose formulation for uncomplicated Plasmodiumfalciparum malaria in Benin: a randomized effectiveness noninferioritytrial. J Infect Dis. 2009; 200:57-65.DOI: 10.1086/599378
10. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethaminein northern Tanzania and the emergence of dhps resistancemutation at codon 581. PLoS ONE. 2009; 4:e4569. DOI:10.1371/journal.pone.0004569
11. World Health Organization. Report of the technical expert groupmeeting on intermittent preventive treatment in pregnancy (IPTp).Geneva, 2007 July 11-13. Geneva: The Organization; 2008.
12. Kalanda GC, Hill J, Verhoeff FH, Brabin BJ. Comparative effi cacyof chloroquine and sulphadoxine-pyrimethamine in pregnant womenand children: a meta-analysis. Trop Med Int Health. 2006; 11:569-77.DOI: 10.1111/j.1365-3156.2006.01608.x
13. Tagbor H, Bruce J, Ord R, Randall A, Browne E, Greenwood B, et al. Comparison of the therapeutic efficacy of chloroquine and sulphadoxine-pyrimethamine in children and pregnant women. Trop Med Int Health. 2007;12:1288-97.DOI: 10.1111/j.1365-3156.2007.01927.x
14. Mutabingwa TK, Muze K, Ord R, Briceño M, Greenwood BM, Drakeley C, et al. Randomized trial of artesunate + amodiaquine,sulfadoxine-pyrimethamine + amodiaquine, chlorproguanal-dapsoneand SP for malaria in pregnancy in Tanzania. PLoS ONE.2009;4:e5138. DOI: 10.1371/journal.pone.0005138
15. Briand V, Denoeud L, Massougbodji A, Cot M. Effi cacy of intermittentpreventive treatment versus chloroquine prophylaxis to preventmalaria during pregnancy in Benin. J Infect Dis. 2008;198:594-601.DOI: 10.1086/590114
16. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, et al. Competitive facilitation of drug-resistantPlasmodium falciparum malaria parasites in pregnant womenwho receive preventive treatment. Proc Natl Acad Sci U S A.2009;106:9027-32.DOI: 10.1073/pnas.0901415106
17. Basco LK, Eldin de Pécoulas P, Wilson CM, Le Bras J, Mazabraud A. Point mutations in the dihydrofolate reductase-thymidylate synthasegene and pyrimethamine and cycloguanil resistance in Plasmodiumfalciparum. Mol Biochem Parasitol. 1995;69:135-8.DOI:10.1016/0166-6851(94)00207-4
18. Curtis J, Duraisingh MT, Trigg JK, Mbwana H, Warhurst DC, Curtis CF. Direct evidence that asparagine at position 108 of thePlasmodium falciparum dihydrofolate reductase is involved in resistanceto antifolate drugs in Tanzania. Trans R Soc Trop Med Hyg.1996; 90:678-80.DOI: 10.1016/S0035-9203(96)90432-0
19. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE. Sequencevariation of the hydroxymethyldihydropterin pyrophosphokinase:dihydropteroate synthase gene in lines of the human malariaparasite, Plasmodium falciparum, with differing resistance to sulfadoxine.Eur J Biochem. 1994; 224:397-405.DOI: 10.1111/j.1432-1033. 1994.00397.x
20. Wang P, Read M, Sims PF, Hyde JE. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol. 1997; 23:979-86.DOI: 10.1046/j.1365-2958.1997.2821646.x
21. Djimdé A, Doumbo OK, Steketee RW, Plowe CV. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet. 2001;358:890-1.DOI: 10.1016/S0140-6736-(01)06040-8
22. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis. 2001;184:770-6.DOI: 10.1086/322858
23. Laufer MK, Djimdé AA, Plowe CV. Monitoring and deterring drugresistant malaria in the era of combination therapy. Am J Trop Med Hyg. 2007;77:160-9.
24. Tahar R, Basco LK. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children. Acta Trop. 2007;103:81-9.DOI: 10.1016/j.actatropica.2007.04.008
25. Bonnet M, Roper C, Félix M, Coulibaly L, Kankolongo GM, Guthmann JP. Effi cacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré. Malar J. 2007; 6:54.DOI: 10.1186/1475-2875-6-54
26. Ndounga M, Tahar R, Basco LK, Casimiro PN, Malonga DA, Ntoumi F. Therapeutic effi cacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo. Trop Med Int Health. 2007;12:1164-71.DOI: 10.1111/j.1365-3156.2007.01904.x
27. Karema C, Imwong M, Fanello CI, Stepniewska K, Uwimana A, Nakeesathit S, et al. Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2010; 54:477-83 DOI: 10.1128/AAC.00498-09
28. Mockenhaupt FP, Bedu-Addo G, Eggelte TA, Hommerich L, Holmberg V, von Oertzen C, et al. Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana. J Infect Dis. 2008;198:1545-9.DOI: 10.1086/592455
29. Bouyou-Akotet MK, Mawili-Mboumba DP, Tchantchou Tde D, Kombila M. High prevalence of sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon. J Antimicrob Chemother. 2010;65:438-41.DOI: 10.1093/jac/dkp467
30. Tinto H, Ouédraogo JB, Zongo I, van Overmeir C, van Marck E, Guiguemdé TR, et al. Sulfadoxine-pyrimethamine effi cacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. Am J Trop Med Hyg. 2007; 76:608-13.
31. Mockenhaupt FP, Eggelte TA, Böhme T, Thompson WN, Bienzle U. Plasmodium falciparum dihydrofolate reductase alleles and pyrimethamine use in pregnant Ghanaian women. Am J Trop Med Hyg. 2001;65:21-6.
32. World Health Organization. Assessment and monitoring of antimalarial drug effi cacy for the treatment of uncomplicated falciparum malaria. Geneva: The Organization; 2003. WHO/HTM/RBM/2003.50.
33. Briand V, Bottero J, Noël H, Masse V, Cordel H, Guerra J, et al. Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefl oquine. J Infect Dis. 2009;200:991-1001.DOI: 10.1086/605474
34. Bouyou-Akotet MK, Nzenze-Afene S, Ngoungou EB, Kendjo E, Owono-Medang M, Lekana-Douki JB, et al. Burden of malaria during pregnancy at the time of IPTp/SP implementation in Gabon. Am J Trop Med Hyg. 2010; 82:202-9.DOI: 10.4269/ajtmh.2010.09-0267
35. Enato EF, Mens PF, Okhamafe AO, Okpere EE, Pogoson E, Schallig HD. Plasmodium falciparum malaria in pregnancy: prevalence of peripheral parasitaemia, anaemia and malaria care-seeking behaviour among pregnant women attending two antenatal clinics in Edo State, Nigeria. J Obstet Gynaecol. 2009;29:301-6.DOI: 10.1080/01443610902883320
36. Ofori M, Ansah E, Agyepong I, Ofori-Adjei D, Hviid L, Akanmori B. Pregnancy-associated malaria in a rural community of Ghana. Ghana Med J. 2009;43:13-8.
37. Peters PJ, Thigpen MC, Parise ME, Newman RD. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 2007;30:481-501.DOI: 10.2165/00002018-200730060-00003
38. Basco LK. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. Geneva: World Health Organization; 2007.
39. Cot M, Brutus L, Pinell V, Ramaroson H, Raveloson A, Rabeson D, et al. Malaria prevention during pregnancy in unstable transmission areas: the highlands of Madagascar. Trop Med Int Health. 2002;7:565-72.DOI: 10.1046/j.1365-3156.2002.00897.x
40. Steketee RW, Wirima JJ, Hightower AW, Slutsker L, Heymann DL, Breman JG. The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Am J Trop Med Hyg. 1996; 55:33-41.